Iasocholine

Fluorocholine (18F) chloride, the active ingredient in Iasocholine, is a radiopharmaceutical presented as a sterile injectable solution for intravenous use. It is employed in positron emission tomography (PET) imaging to assess choline metabolism in certain tumors and related conditions.

GNH USA supplies Iasocholine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic imaging centres and oncology clinics worldwide, complying with EU regulatory standards.

Iasocholine, a fluorine‑18 labeled choline analogue, is used in PET imaging to evaluate abnormal cellular proliferation in oncology and neurology.

- Prostate cancer recurrence: helps locate sites of biochemical relapse when PSA rises. - Brain tumors: assists in delineating high‑grade gliomas and assessing treatment response. - Hepatocellular carcinoma: aids in detecting primary liver lesions and metastatic disease.

Adverse reactions to Iasocholine are generally mild but can vary.

Common Side Effects: - Injection site pain or erythema. - Transient nausea. - Brief flushing or warmth sensation. - Mild headache.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Radiation‑induced skin injury at the injection site. - Significant hypotension. - Cardiac arrhythmia (rare).

Use of Iasocholine requires careful consideration of patient‑specific factors.

- Pregnancy: avoid unless essential, as radiation exposure may affect the fetus. - Breastfeeding: discontinue nursing for an appropriate interval after administration. - Renal impairment: assess renal function, as clearance may be reduced. - Known hypersensitivity: evaluate for allergy to fluorocholine or excipients. - Recent administration of other radiopharmaceuticals: schedule scans to avoid overlap. - Store at ambient temperature: keep in original container, protect from light and moisture.

Iasocholine may interact with other agents that influence imaging quality or patient physiology.

Major Interactions (Avoid): - Concurrent administration of other radiopharmaceuticals emitting similar energy, which can confound PET interpretation. - High‑dose iodinated contrast within 24 hours, potentially altering tracer distribution.

Moderate Interactions (Monitor Closely): - Anticholinergic medications that may reduce choline transporter activity. - Systemic steroids that can modify tumor metabolism. - Diuretics affecting renal clearance of the tracer. - Beta‑blockers influencing hemodynamic response during imaging.